Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

TARGETED THERAPIES

JAK inhibitors and VTE risk: how concerned should we be?

Nature Reviews Rheumatology volume 17, pages 133–134 (2021)Cite this article

Subjects

Janus kinase (JAK) inhibitors have become standard treatment for patients with rheumatoid arthritis who do not respond well to other DMARDs. Concerns have been raised over an increased risk of venous thromboembolism with JAK inhibitors, tempering enthusiasm for their use in the clinic, but are these concerns justified?

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Winthrop, K. L. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat. Rev. Rheumatol. 13, 234–243 (2017).

    Article  CAS  Google Scholar 

  2. Yates, M. et al. Venous thromboembolism risk with JAK inhibitors: a meta-analysis. Arthritis Rheumatol. https://doi.org/10.1002/art.41580 (2020).

    Article  PubMed  Google Scholar 

  3. Genovese, M. et al. Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis. Lancet Rheumatol. 2, E347–E357 (2020).

    Article  Google Scholar 

  4. Mease, P. et al. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data. Ann. Rheum. Dis. 79, 1400–1413 (2020).

    Article  CAS  Google Scholar 

  5. Sandborn, W. J. et al. Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme. Aliment. Pharmacol. Ther. 50, 1068–1076 (2019).

    Article  CAS  Google Scholar 

  6. Cohen, S. B. et al. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann. Rheum. Dis. https://doi.org/10.1136/annrheumdis-2020-218510 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  7. Winthrop, K. et al. Integrated safety of filgotinib in patients with moderately or severely active rheumatoid arthritis receiving treatment for up to 5.5 years [abstract]. Arthritis Rheumatol. 72 (Suppl. 10), 229 (2020).

    Google Scholar 

  8. Choi, H. K. et al. The risk of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a UK population-based outpatient cohort study. Ann. Rheum. Dis. 72, 1182–1187 (2013).

    Article  Google Scholar 

  9. Samuelson, B. T. et al. The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis: a meta-analysis. Blood Coagul. Fibrinolysis 27, 648–652 (2016).

    Article  CAS  Google Scholar 

  10. Molander, V., Bower, H. & Askling, J. Does the risk of venous thromboembolism vary with disease activity in rheumatoid arthritis? [abstract]. Ann. Rheum. Dis. 79 (Suppl. 1), 23–24 (2020).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Metroplex Clinical Research Center, Rheumatology Department, THR Presbyterian Hospital, Dallas, TX, USA

    Stanley B. Cohen

  2. University of Texas Southwestern Medical School, Dallas, TX, USA

    Stanley B. Cohen

Authors
  1. Stanley B. Cohen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stanley B. Cohen.

Ethics declarations

Competing interests

S.B.C. declares they have been a consultant and investigator for Abbvie, Eli Lilly, Gilead and Pfizer.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cohen, S.B. JAK inhibitors and VTE risk: how concerned should we be?. Nat Rev Rheumatol 17, 133–134 (2021). https://doi.org/10.1038/s41584-021-00575-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41584-021-00575-5

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing